헬리코박터 파일로리 진단 시장 : 검사 유형별, 제품 유형, 기술, 연령층, 최종 사용자별 예측(2026-2032년)

The Helicobacter Pylori Diagnostics Market is projected to grow by USD 1,487.30 million at a CAGR of 7.34% by 2032.

Helicobacter pylori diagnostics are central to the prevention, diagnosis, and management of gastritis, peptic ulcer disease, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer risk. The organism is classified by the International Agency for Research on Cancer as a Group 1 carcinogen, making accurate detection, eradication confirmation, and resistance-aware care a public health priority.

Demand is supported by guideline-based use of noninvasive urea breath tests, stool antigen tests, serology in selected settings, endoscopic biopsy-based histology, rapid urease testing, culture, and molecular assays. Momentum is strongest where clinicians are shifting from one-time detection toward test-and-treat pathways, post-treatment eradication confirmation, and antimicrobial resistance surveillance.

Transformative Shifts in the H. Pylori Testing Landscape

The landscape is moving from empiric, symptom-led testing to evidence-based pathways that align diagnostics with eradication therapy. Current clinical guidance increasingly emphasizes confirmation of active infection and test-of-cure after treatment, supporting higher use of urea breath and stool antigen testing over antibody-only approaches when active infection status is required.

A second structural shift is the rise of molecular testing for clarithromycin and other resistance markers. As H. pylori antibiotic resistance has increased globally, laboratories, gastroenterology practices, and public health systems are prioritizing diagnostics that can improve treatment selection, reduce repeat therapy, and support antimicrobial stewardship. This transition is also increasing the importance of validated sample handling, assay standardization, and clinically interpretable reporting.

Cumulative Impact of Artificial Intelligence on H. Pylori Diagnostics

Artificial intelligence is adding cumulative value across the H. pylori diagnostics workflow rather than replacing validated assays. In endoscopy, AI-enabled image analysis is being studied to support detection of gastritis patterns associated with infection, while digital pathology tools can assist review of biopsy slides and standardize interpretation where specialist capacity is constrained.

AI also strengthens operational performance. Predictive analytics can identify higher-risk populations for targeted testing, automate quality checks in laboratories, and improve planning for diagnostic kit utilization. The strongest near-term impact is expected where AI is paired with regulated tests, electronic health records, endoscopy data, pathology images, and antimicrobial resistance information to guide clinically actionable decisions.

Key Regional Insights Across Major H. Pylori Diagnostics Markets

Asia-Pacific carries a high clinical burden because many countries combine large populations, variable sanitation history, and substantial gastric cancer prevention needs; this supports broad use of noninvasive testing and endoscopy-linked diagnosis. North America is characterized by guideline-driven testing, strong reimbursement scrutiny, established laboratory networks, and increasing attention to post-treatment confirmation, while Latin America shows rising demand as access to gastroenterology, private laboratories, and hospital-based diagnostic infrastructure expands.

In Europe, organized clinical pathways, antimicrobial stewardship, and resistance-aware management support adoption of validated breath, stool, histology, and molecular tests. The Middle East is shaped by investment in tertiary care, medical tourism, and higher testing access in urban centers, especially where specialist gastroenterology services are concentrated. Africa remains heterogeneous, with major opportunities in affordable stool antigen testing, decentralized diagnostics, public health education, and capacity building for endoscopy, pathology, and laboratory quality systems.

Key Group Insights for ASEAN, GCC, EU, BRICS, G7, and NATO

Within ASEAN, demand is linked to urban healthcare expansion, private diagnostics growth, improving endoscopy access, and gastric disease awareness, while the GCC benefits from modern hospital networks, high healthcare investment, and increasing use of advanced diagnostic platforms in specialty care. The European Union is guided by harmonized quality expectations, regulated in vitro diagnostic pathways, antimicrobial stewardship, and clinical preference for accurate active-infection testing.

Across BRICS, large patient pools and uneven access create parallel demand for low-cost, high-volume tests and advanced molecular solutions that support resistance-aware treatment. G7 countries lead in guideline adoption, quality management, digital health integration, and test-of-cure compliance. NATO members overlap with many advanced economies where supply security, laboratory resilience, regulated procurement, and continuity of essential diagnostics are increasingly strategic healthcare considerations.

Key Country Insights for Priority H. Pylori Diagnostics Markets

The United States and Canada show strong use of guideline-based noninvasive testing, with emphasis on eradication confirmation, appropriate test selection, and avoidance of serology when active infection status is needed. Mexico and Brazil present expanding opportunities as private laboratories, hospital networks, and gastric disease awareness grow. In Europe, the United Kingdom, Germany, France, Italy, and Spain support demand through established gastroenterology services, laboratory accreditation, and stewardship-focused care pathways, while Russia combines large geographic need with variable regional access to specialist diagnostics.

In Asia-Pacific, China, India, and Japan are pivotal because of large populations, high gastric disease relevance, and growing investment in diagnostics; Japan also has longstanding gastric cancer prevention practices that support structured H. pylori management and eradication confirmation. Australia maintains high standards for validated testing and evidence-based reimbursement decisions, and South Korea benefits from advanced endoscopy capacity, strong hospital infrastructure, and national attention to gastric cancer screening.

Actionable Recommendations for H. Pylori Diagnostics Leaders

Industry leaders should prioritize assays that detect active infection, support test-of-cure, and fit local clinical workflows. Urea breath and stool antigen platforms should be positioned around accuracy, patient convenience, pre-analytical reliability, and compliance with guideline-based care, while molecular tests should emphasize resistance detection and treatment optimization.

Commercial strategies should combine clinician education, payer evidence, laboratory partnerships, and region-specific affordability models. Leaders should document analytical and clinical performance, reduce turnaround time, ensure supply continuity, support quality-control programs, and integrate results into digital care pathways. Differentiation will increasingly depend on usability, resistance-aware reporting, regulatory readiness, and the ability to improve eradication outcomes without adding workflow complexity.

Research Methodology for the H. Pylori Diagnostics Analysis

The research approach integrates secondary analysis of clinical guidelines, regulatory frameworks, peer-reviewed literature, public health references, antimicrobial resistance reports, and in vitro diagnostics industry disclosures. Sources are evaluated for relevance to H. pylori detection, active-infection confirmation, post-treatment testing, resistance surveillance, test performance, and regional access conditions.

Market interpretation is supported by triangulation across test modality adoption, healthcare infrastructure, reimbursement practices, disease burden indicators, laboratory capacity, endoscopy availability, and expert-informed assessment of diagnostic workflows. Findings are validated for consistency with established gastroenterology, oncology prevention, infectious disease, and laboratory medicine standards rather than unsupported market-size or forecasting claims.

Conclusion: Strategic Outlook for Helicobacter Pylori Diagnostics

The Helicobacter pylori diagnostics landscape is evolving from basic infection identification toward precision-oriented management that confirms active disease, verifies eradication, and addresses antibiotic resistance. This shift strengthens the role of high-quality noninvasive tests, molecular assays, endoscopy-linked diagnostics, and integrated laboratory services.

Organizations that align product development with clinical guidelines, regional affordability, AI-enabled workflow improvement, laboratory quality standards, and antimicrobial stewardship will be well positioned to support sustainable growth while improving outcomes in gastric disease prevention and treatment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Helicobacter Pylori Diagnostics Market, by Test Type

• 7.1. Non-Invasive Tests
  • 7.1.1. Urea Breath Test
  • 7.1.2. Stool Antigen Test
  • 7.1.3. Serology Test
• 7.2. Invasive Tests
  • 7.2.1. Endoscopy-Based Diagnosis
  • 7.2.2. Biopsy-Based Tests
    • 7.2.2.1. Rapid Urease Test
    • 7.2.2.2. Histology
    • 7.2.2.3. Culture Test
    • 7.2.2.4. Molecular Tests (PCR)

8. Helicobacter Pylori Diagnostics Market, by Product Type

• 8.1. Consumables
  • 8.1.1. Kits
  • 8.1.2. Reagents
  • 8.1.3. Test Strips
• 8.2. Instruments
  • 8.2.1. Breath Test Analyzers
  • 8.2.2. Endoscopy Equipment
  • 8.2.3. PCR Systems

9. Helicobacter Pylori Diagnostics Market, by Technology

• 9.1. Immunoassay-Based Diagnostics
  • 9.1.1. ELISA Tests
  • 9.1.2. Rapid Test Kits
• 9.2. Molecular Diagnostics
• 9.3. Breath Analysis Technology
• 9.4. Microbiological Culture Methods
• 9.5. Histopathology Techniques

10. Helicobacter Pylori Diagnostics Market, by Age Group

• 10.1. Pediatric
• 10.2. Adult
• 10.3. Geriatric

11. Helicobacter Pylori Diagnostics Market, by End User

• 11.1. Ambulatory Care Centers
• 11.2. Clinics
• 11.3. Diagnostic Laboratories
• 11.4. Hospitals

12. Helicobacter Pylori Diagnostics Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Helicobacter Pylori Diagnostics Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Helicobacter Pylori Diagnostics Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Thermo Fisher Scientific Inc.
• 16.2. Abbott Laboratories
• 16.3. F. Hoffmann-La Roche Ltd
• 16.4. Bio-Rad Laboratories, Inc.
• 16.5. Quest Diagnostics Incorporated
• 16.6. bioMerieux SA
• 16.7. DiaSorin S.p.A.
• 16.8. Meridian Bioscience, Inc.
• 16.9. Alere Inc.
• 16.10. Alpha Laboratories Ltd.
• 16.11. Becton, Dickinson and Company
• 16.12. Cardinal Health, Inc.
• 16.13. Certest Biotec S.L.
• 16.14. Coris BioConcept
• 16.15. Diagnostic BioSystems, Inc
• 16.16. EKF Diagnostics Holdings plc
• 16.17. Epitope Diagnostics, Inc.
• 16.18. Exalenz Bioscience Ltd.
• 16.19. Halyard Health, Inc.
• 16.20. Medix Biochemica Oy
• 16.21. Medline Industries, Inc.
• 16.22. MP Biomedicals, LLC
• 16.23. QuidelOrtho Corporation
• 16.24. Savyon Diagnostics Ltd.
• 16.25. Sekisui Diagnostics LLC